Interstitial lung disease and anti-TNF-alpha therapy in rheumatoid arthritis: Two different patterns?

The first lung complications of anti-TNF-alpha therapy in rheumatoid arthritis (RA) that were reported were infections. Recently, interstitial lung disease (ILD) has been described as a consequence of this treatment. We report two cases of women treated with anti-TNF-alpha therapy for RA who both de...

Full description

Saved in:
Bibliographic Details
Published inRevue des maladies respiratoires Vol. 27; no. 3; p. 232
Main Authors Schuller, A, Coudurier, M, Lega, J-C, Khouatra, C, Cottin, V, Cordier, J-F
Format Journal Article
LanguageFrench
Published France 01.03.2010
Subjects
Arthritis, Rheumatoid - drug therapy
Female
Humans
Lung Diseases, Interstitial - chemically induced
Middle Aged
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online AccessGet more information

Cover

More Information
Summary:The first lung complications of anti-TNF-alpha therapy in rheumatoid arthritis (RA) that were reported were infections. Recently, interstitial lung disease (ILD) has been described as a consequence of this treatment. We report two cases of women treated with anti-TNF-alpha therapy for RA who both developed exacerbations of their preexisting ILD thought to be due to the treatment. In one case, this complication occurred 2 months after anti-TNF-alpha therapy, whereas the delay of occurrence was 26 months in the second case. Based on these two cases and on the first 40 observations in the literature, we hypothesize that ILD may be exacerbated according to two distinct patterns during anti-TNF-alpha treatment for RA, occurring early (most frequently) or late after treatment was started, with a mean of 4 and 26 months, respectively. Other features that may differ between these two presentations include the risk factors, the anti-TNF-alpha molecule used, the histopathological pattern, and the prognosis.
ISSN:1776-2588